IRIX, US4626841013

IRIDEX stock: Revenue falls 19%, 2026 outlook cut

Published on 11/19/2026 at 02:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
IRIDEX stock faces a lower 2026 revenue outlook after weak international demand hit third-quarter sales. Margin gains did not offset the softer top line.

Key points for investors

  • IRIDEX reported third-quarter revenue of USD 10.2 million and a net loss of USD 1.4 million.
  • Gross margin improved to 42.4%, while adjusted EBITDA remained negative.
  • Management cited weaker international demand, distributor inventory adjustments and regulatory challenges.
IRIX, US4626841013, Illustration mit AI erstellt.

IRIDEX Corporation lowered its full-year 2026 revenue outlook after reporting weaker-than-expected third-quarter sales on November 17. In a release published by GlobeNewswire, the ophthalmic device maker said revenue fell amid weaker international retina sales, lower probe orders and distributor inventory adjustments.

Revenue outlook moves lower

Revenue for the quarter ended October 3, 2026, was USD 10.2 million, down 19% from USD 12.5 million a year earlier. Retina product revenue declined to USD 5.1 million from USD 6.7 million, while Cyclo G6 product family revenue fell to USD 3.2 million from USD 3.5 million.

IRIDEX now expects full-year revenue of USD 46 million to USD 48 million, compared with its previous range of USD 51 million to USD 53 million. The outlook excludes revenue from the Middle East. Management attributed the weaker outlook to demand in Europe and Asia, delayed orders, distributor inventory levels and regulatory challenges.

Margins improve as losses persist

Gross margin rose to 42.4% from 32.1% in the prior-year quarter. The comparison benefited from an approximately USD 0.8 million inventory write-off in the year-earlier period; excluding that effect, pro forma gross margin was 38.7%, an improvement of 370 basis points.

Operating expenses were USD 5.5 million, broadly unchanged from USD 5.4 million. Net loss narrowed to USD 1.4 million, or USD 0.08 per share, from USD 1.6 million, or USD 0.09 per share. Non-GAAP adjusted EBITDA was a loss of USD 0.6 million, compared with a loss of USD 0.1 million a year earlier.

Cash and cash equivalents stood at USD 3.7 million on October 3, down USD 1.0 million from July 4. The company expects cash use to decline as safety-stock inventory is consumed and said it is reviewing product lines to focus resources on more profitable opportunities.

Iridex business and market position

Iridex develops, manufactures and markets laser-based medical systems, delivery devices and consumable probes for ophthalmology. Its MicroPulse technology and product portfolio target glaucoma, diabetic macular edema and other retinal diseases. The company sells through a direct US sales force and independent distributors in more than 100 countries, and is based in San Jose, California.

IRIDEX company details

  • Company: Iridex Corporation
  • ISIN: US4626841013
  • Ticker: IRIX
  • Exchange: Nasdaq Capital Market
  • Reported quarter: Ended October 3, 2026

The US market environment is covered in the S&P 500 market section.

More news and analyses on IRIDEX stock are available on the company topic page.

Disclaimer...
en | US4626841013 | IRIX | boerse | 70533269 | bgmi